Biotechnology Approaches for the Treatment of Dyslipidemia
- 9 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 35 (1), 167-183
- https://doi.org/10.1007/s10557-020-07017-6
Abstract
Background Despite advances in the development of lipid-lowering therapies, clinical trials have shown that a significant residual risk of cardiovascular disease persists. Specifically, new drugs are needed for non-responding or statin-intolerant subjects or patients considered at very high risk for cardiovascular events even though are already on treatment with the best standard of care. Results and Conclusions Besides, genetic and epidemiological studies and Mendelian randomization analyses have strengthened the linear correlation between the concentration of low-density lipoprotein cholesterol (LDL-C) and the incidence of cardiovascular events and highlighted various novel therapeutic targets. This review describes the novel strategies to reduce the levels of LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a), focusing on those developed using biotechnology-based strategies.Keywords
Funding Information
- MIUR Progetto Eccellenza
This publication has 159 references indexed in Scilit:
- Apolipoprotein C-IIICirculation Research, 2013
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial HypercholesterolemiaCirculation, 2012
- Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins: EVIDENCE THAT ApoC-III PLAYS A MAJOR ROLE IN THE FORMATION OF LIPID PRECURSORS WITHIN THE MICROSOMAL LUMEN*Online Journal of Public Health Informatics, 2011
- Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDLBritish Journal of Pharmacology, 2011
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In VivoPLOS ONE, 2010
- Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humansJCI Insight, 2008
- A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent CardioprotectionScience, 2008
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseThe New England Journal of Medicine, 2006
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences of the United States of America, 2003